Nycomed UK has appointed Santé to handle a UK PR programme for Angiox after a three-way pitch understood to have been against Right Angle Learning and freelance PRO Colin Martin.
The European Medicines Agency recommended that Angiox should obtain European marketing approval as an antithrombotic three months ago. Nycomed expects to launch the product across Europe before the year’s end.
Angiox prevents blood clotting and is referred to as a thrombin-specific anticoagulant, because it targets the enzyme responsible for forming bloodclots. It is an alternative to clot-preventer hepirin and additional antiplatelet drugs.
Santé reports to senior product manager Reman McDonagh. The agency, which worked with McDonagh in her former marketing role at Roche Products, has a contract that runs until the end of 2005.
Angiox is known as Angiomax in the US, where it has been available since 2001. It is used during angioplasty or PCI – percutaneous coronary intervention.
The UK government announced plans earlier this year to significantly boost its spending on PCI.